User profiles for Boris Pasche
Boris PascheWake Forest Comprehensive Cancer Center Verified email at wakehealth.edu Cited by 11555 |
Role of transforming growth factor beta in cancer
B Pasche - Journal of cellular physiology, 2001 - Wiley Online Library
Transforming growth factor beta (TGF‐β) is an effective and ubiquitous mediator of cell
growth. The significance of this cytokine in cancer susceptibility, cancer development and …
growth. The significance of this cytokine in cancer susceptibility, cancer development and …
TGF-β: duality of function between tumor prevention and carcinogenesis
…, HG Munshi, L Bartholin, B Pasche… - Journal of the …, 2014 - academic.oup.com
Several mechanisms underlying tumor progression have remained elusive, particularly in
relation to transforming growth factor beta (TGF-β). Although TGF-β initially inhibits epithelial …
relation to transforming growth factor beta (TGF-β). Although TGF-β initially inhibits epithelial …
Transforming growth factor β as a therapeutic target in systemic sclerosis
Transforming growth factor β (TGF-β) is a pleiotropic cytokine with vital homeostatic
functions. Aberrant TGF-β expression is implicated in the pathogenesis of fibrosis in systemic …
functions. Aberrant TGF-β expression is implicated in the pathogenesis of fibrosis in systemic …
MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells
…, V Liberal, A Chatterjee, R Kirchwegger, B Pasche… - Nature, 2001 - nature.com
The mitotic checkpoint protein hsMad2 is required to arrest cells in mitosis when chromosomes
are unattached to the mitotic spindle 1 . The presence of a single, lagging chromosome is …
are unattached to the mitotic spindle 1 . The presence of a single, lagging chromosome is …
Diagnosis of thyroid cancer using deep convolutional neural network models applied to sonographic images: a retrospective, multicohort, diagnostic study
Background The incidence of thyroid cancer is rising steadily because of overdiagnosis and
overtreatment conferred by widespread use of sensitive imaging techniques for screening. …
overtreatment conferred by widespread use of sensitive imaging techniques for screening. …
The platelet function defect of cardiopulmonary bypass [see comments]
…, H MacGregor, V Birjiniuk, H Ouimet, B Pasche… - 1993 - ashpublications.org
The use of cardiopulmonary bypass (CPB) during cardiac surgery is associated with a
hemostatic defect, the hallmark of which is a markedly prolonged bleeding time. However, the …
hemostatic defect, the hallmark of which is a markedly prolonged bleeding time. However, the …
Genetic/familial high-risk assessment: breast and ovarian
All cancers develop as a result of mutations in certain genes, such as those involved in the
regulation of cell growth and/or DNA repair, 1, 2 but not all of these mutations are inherited …
regulation of cell growth and/or DNA repair, 1, 2 but not all of these mutations are inherited …
TGF-β signaling alterations and susceptibility to colorectal cancer
Y Xu, B Pasche - Human molecular genetics, 2007 - academic.oup.com
In 2006, more than 55 000 patients died of colorectal cancer in the US, accounting for ∼10%
of all cancer deaths. Despite significant progress in screening combined with the …
of all cancer deaths. Despite significant progress in screening combined with the …
Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis
Up to 30% of patients with metastatic breast cancer eventually develop brain metastasis, yet
the pathologic mechanism behind this development remains poorly understood. Here, we …
the pathologic mechanism behind this development remains poorly understood. Here, we …
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Background Regorafenib confers an overall survival benefit in patients with refractory metastatic
colorectal cancer; however, the adverse event profile of regorafenib has limited its use. …
colorectal cancer; however, the adverse event profile of regorafenib has limited its use. …